NVIC Articles

Uncategorized

Latest articles

Browse Articles

Placeholder image
Page

According to the CDC, individuals receiving meningococcal vaccines targeting meningococcal serogroups A, C, Y, and W-135 (Menactra or Menveo) may experience mild side effects such as pain or redness at...

Placeholder image
Page

In October 2023, the FDA approved use of PENBRAYA, a pentavalent meningococcal vaccine targeting the A, B, C, W, and Y meningococcal serogroups. According to the vaccine’s package insert, the...

Placeholder image
Page

Meningococcal serogroup B (MenB) vaccines received FDA approval based on blood tests indicating immune response (immunogenicity) to the particular strains found within the vaccine. Meningococcal serogroup B strains, however, are...

Placeholder image
Page

MenQuadfi received FDA approval 2020 based on clinical trials that reported the vaccine was not inferior in safety or immunogenicity when compared with Menomune, Menactra, and Menveo conjugate vaccines.  ...

Placeholder image
Page

Approved by the FDA in 2010, Menveo (serogroups A, C, Y, and W-135) conjugate vaccine approval was based on safety and immunogenicity studies reporting the vaccine to be non-inferior to...

Placeholder image
Page

Clinical trials on Menactra’s (MCV4 or MenACWY-D) efficacy were not a requirement when FDA licensed its use in 2005. Menactra was the first meningococcal (serogroups A, C, Y, and W-135)...

Placeholder image
Page

Meningococcal vaccine recommendations are scheduled to be reviewed in the next 15 months. Potential changes to the meningococcal recommendations may potentially include the elimination of the age 11–12-year-old meningococcal vaccine...

Placeholder image
Page

On October 20, 2023, the FDA approved PENBRAYA, a meningococcal conjugate vaccine targeting meningococcal serogroups A, B, C, Y, and W-135. This vaccine was approved in individuals between the ages...

Placeholder image
Page

The first meningococcal serogroup B vaccine, TRUMENBA, manufactured by Wyeth (Pfizer) pharmaceuticals, received FDA approval for use in persons aged 10 through 25 years of age on October 29, 2014. ...

Placeholder image
Page

The first meningococcal conjugate vaccine, Menactra, manufactured by Sanofi Pasteur, received FDA approval in January 2005 for use in persons ages 11 through 55 years.  Menactra (MCV4 or MenACWY-D), a...

Topics
Select disease / vaccine